Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Operating Leases (2019 - 2025)

Assembly Biosciences has reported Operating Leases over the past 7 years, most recently at $2.1 million for Q4 2025.

  • Quarterly results put Operating Leases at $2.1 million for Q4 2025, down 21.65% from a year ago — trailing twelve months through Dec 2025 was $2.1 million (down 21.65% YoY), and the annual figure for FY2025 was $2.1 million, down 21.65%.
  • Operating Leases for Q4 2025 was $2.1 million at Assembly Biosciences, down from $2.2 million in the prior quarter.
  • Over the last five years, Operating Leases for ASMB hit a ceiling of $5.6 million in Q1 2021 and a floor of $50000.0 in Q3 2023.
  • Median Operating Leases over the past 5 years was $1.9 million (2022), compared with a mean of $1.9 million.
  • Biggest five-year swings in Operating Leases: crashed 96.96% in 2022 and later skyrocketed 1853.1% in 2025.
  • Assembly Biosciences' Operating Leases stood at $3.3 million in 2021, then crashed by 96.96% to $101000.0 in 2022, then skyrocketed by 1010.89% to $1.1 million in 2023, then skyrocketed by 134.22% to $2.6 million in 2024, then decreased by 21.65% to $2.1 million in 2025.
  • The last three reported values for Operating Leases were $2.1 million (Q4 2025), $2.2 million (Q3 2025), and $2.4 million (Q2 2025) per Business Quant data.